# OnCo record aml-secondary (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml-secondary/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml-secondary" ;
  schema:name "Secondary and therapy-related acute myeloid leukaemia"@en ;
  schema:alternateName "Therapy-related AML"@en, "t-AML"@en, "Secondary AML"@en, "AML with myelodysplasia-related changes"@en, "AML arising from MDS or MPN"@en ;
  schema:description "Secondary acute myeloid leukaemia grows out of an earlier marrow disorder or follows chemotherapy or radiotherapy for another cancer. It resists standard treatment more than other leukaemias; a liposomal form of the two classic chemotherapy drugs, CPX-351, lengthens life in fit older patients, and transplant is the only route to cure."@en ;
  schema:url <https://onco.cc/cancers/aml-secondary/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/cd47-blockade/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cd47/> ;
  onco:pathways <https://onco.cc/pathways/clonal-haematopoiesis/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/eln-risk/>, <https://onco.cc/terms/hma/> ;
  onco:pipeline <https://onco.cc/drugs/cpx-351/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/ideas/idea-chip-risk-modifiers/> ;
  onco:standardOfCare <https://onco.cc/drugs/cpx-351/>, <https://onco.cc/trials/cpx-351-301/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine/>, <https://onco.cc/trials/viale-a/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/revumenib/> .